Valbenazine · Ingrezza

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Tardive Dyskinesia, Huntington's Disease Chorea, Huntington's Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
JP
  • Tardive dyskinesia (DYSVAL capsules 40 mg, Mitsubishi Tanabe Pharma)
Product first approved 2022tabletscapsules.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Huntington's Disease
NCT06312189 · Neurocrine Biosciences
2024-04-24 – 2028-04 · Chorea, Huntington
What this study did
NCT04400331 · Neurocrine Biosciences
2020-09-18 – 2025-11-05 · Chorea, Huntington
What this study did
Tardive Dyskinesia
NCT02736955 · Neurocrine Biosciences
2016-06-13 – 2017-06-30 · Tardive Dyskinesia
What this study did
Other / comorbidity
NCT05206513 · Neurocrine Biosciences
2022-04-15 – 2026-03-31 · Dyskinesia, Cerebral Palsy
What this study did
NCT05110157 · Neurocrine Biosciences
2021-11-29 – 2025-02-18 · Schizophrenia
What this study did
NCT05654870 · Neurocrine Biosciences
2023-01-05 – 2023-11-08 · Schizophrenia
What this study did
Phase 2 (13)
Tardive Dyskinesia
NCT01733121 · Neurocrine Biosciences
2012-12 – 2013-12 · Tardive Dyskinesia
What this study did
NCT01688037 · Neurocrine Biosciences
2012-09 – 2013-10 · Tardive Dyskinesia
What this study did
NCT01393600 · Neurocrine Biosciences
2011-08 – 2012-02 · Tardive Dyskinesia
What this study did
NCT01267188 · Neurocrine Biosciences
2011-01 – 2011-03 · Tardive Dyskinesia
What this study did
Other / comorbidity
NCT07111988 · University of Chicago
2026-06 – 2027-12 · Obsessive-Compulsive Disorder
What this study did
NCT05207085 · Yale University
2024-02-02 – 2027-02-15 · Trichotillomania (Hair-Pulling Disorder)
What this study did
NCT03530293 · Neurocrine Biosciences
2018-04-17 – 2019-07-16 · Tourette Syndrome
What this study did
NCT03444038 · Neurocrine Biosciences
2018-02-08 – 2019-07-12 · Tourette Syndrome
What this study did
NCT03732534 · Neurocrine Biosciences
2018-10-17 – 2019-02-18 · Tourette Syndrome
What this study did
NCT03325010 · Neurocrine Biosciences
2017-10-05 – 2018-11-16 · Tourette Syndrome
What this study did
NCT02879578 · Neurocrine Biosciences
2016-07-25 – 2017-11-01 · Tourette Syndrome
What this study did
NCT02679079 · Neurocrine Biosciences
2016-03-23 – 2017-04-14 · Tourette Syndrome
What this study did
NCT02581865 · Neurocrine Biosciences
2015-11 – 2016-12 · Tourette Syndrome
What this study did
Phase 1 (4)
Tardive Dyskinesia
NCT05053321 · Yale University
2024-10-18 – 2025-10-18 · Tardive Dyskinesia
What this study did
Other / comorbidity
NCT02256475 · Neurocrine Biosciences
2014-09 – 2015-12 · Tourette Syndrome
What this study did
NCT01916993 · Neurocrine Biosciences
2013-08 – 2013-12 · Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
What this study did
NCT01910480 · Neurocrine Biosciences
2013-07 – 2013-08 · Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
What this study did
Phase 4 (6)
Tardive Dyskinesia
NCT07105111 · Neurocrine Biosciences
2025-08-29 – 2028-06 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
What this study did
NCT06107829 · Stephen Ruedrich
2025-01 – 2027-02 · Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
What this study did
NCT05859698 · Neurocrine Biosciences
2023-05-09 – 2024-12-27 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
What this study did
NCT03891862 · Neurocrine Biosciences
2019-03-18 – 2020-01-30 · Tardive Dyskinesia (TD)
What this study did
NCT03698331 · Neurocrine Biosciences
2018-09-14 – 2019-04-03 · Tardive Dyskinesia (TD)
What this study did
Other / comorbidity
NCT05157100 · The Orthopedic Foundation
2021-10-19 – 2023-09-15 · Cervical Dystonia
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT06771323 · Virginia Commonwealth University
2024-12-17 – 2027-06 · Cervical Dystonia
What this study did

Competitive landscape

This drug's own stage for Huntington's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Valbenazine (Ingrezza): this drugApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
TanruprubartPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
Ifezuntirgene InilparvovecPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
WVE-003Phase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
BrezosiranPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
RG6662
—(overall)
Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ingrezza (Valbenazine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 2Trichotillomania (Hair-Pulling Disorder)Recruiting
Est. primary completion 2027-02-15 · NCT05207085 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Obsessive-Compulsive DisorderNot yet recruiting
Est. primary completion 2027-12 · NCT07111988 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 3Huntington's DiseaseEnrolling by invitation
Est. primary completion 2028-04 · NCT06312189 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4Tardive DyskinesiaRecruiting
Est. primary completion 2028-06 · NCT07105111 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 December 2025Topline resultKINECT-DCP Phase 3 misses primary and key secondary endpoints
Neurocrine Biosciences · Source ↗
December 2025Topline resultKINECT-DCP Phase 3 (NCT05206513) did not meet its primary or key secondary endpoints
Neurocrine Biosciences · Source ↗
27 February 2025Topline resultKINECT-PRO Phase 4 top-line patient-reported outcome data